Up-to-date in the evolving regulatory requirements by region, every PHDS project team is fully-engaged from program initiation to reporting of results across Phases I-IV of drug development in China.

Our experience, support systems and infrastructure enable us to provide the highest level of program management and services for Phases I-IV clinical trials.

We offer:

●  Infrastructure and supports
●  Quality processes and accurate reporting
●  Regulatory expertises